

**February 16, 2009
FOR IMMEDIATE RELEASE**

**CONTACT:
Andrew Graham
919-595-0318**

AlphaVax Announces New Vice President of Regulatory, Quality and Clinical Operations

Research Triangle Park, N.C. AlphaVax announced today that it has hired Lynn Baird, PhD, as Vice President of Regulatory, Quality and Clinical Operations. In this capacity Lynn will provide leadership and strategic direction in the areas of regulatory and quality affairs and in clinical operations.

"Lynn's experience in directing successful clinical trials, developing regulatory strategy and gaining regulatory approval for clinical trials will complement our existing leadership team. We will look to Lynn to manage the regulatory affairs for in-house programs at AlphaVax as they move through clinical development, as well as coordinate and support regulatory activities of corporate partners involved with our alphavirus vector platform", said Andrew Graham, Vice President of Development at AlphaVax.

Most recently, Lynn was Sr. Vice President, Regulatory, Quality and Clinical Operations with CombinatoRx, Inc. in Cambridge, MA. Previous to that appointment, she held executive management positions for regulatory affairs and quality at Dyax, Curis and CytoTherapeutics. Lynn earned her Ph.D. in Microbiology and Immunology from Virginia Commonwealth University in Richmond, Virginia.

"We are truly delighted to attract someone of Lynn's caliber, capability and expertise. There is no doubt that she will play a significant role in our future growth and success as we advance multiple vaccine products through clinical development", said Jonathan Gelles, Chairman of AlphaVax's Board of Directors.

About AlphaVax

AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a proprietary alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the same manufacturing, formulation, and delivery strategies to be applied to many different products. The company's business strategy is to maximize the potential of this platform through a mixture of in-house and partnered programs. The AlphaVax technology is currently being used to advance vaccines for influenza, cytomegalovirus, herpes simplex virus, respiratory syncytial virus, a range of cancers, HIV and a number of biodefense targets. The AlphaVax headquarters and R&D facilities are located in Research Triangle Park, and its GMP-compliant manufacturing facility is located in Lenoir, NC.

###